glaucoma

Pelvic organ prolapse may be clue to presence of exfoliation syndrome
Intracameral prostaglandin analogue therapy delivers durable benefitFive patients receiving an extended-release travoprost delivery system (ENV515, Envisia Therapeutics) in the anterior chamber have ongoing IOP-lowering with follow-up to 9 months in an ongoing study.
How oral and dental hygiene plays a role in glaucomaIn the past couple of years, there has been discussion regarding dental and oral health—specifically the oral biomicrome—as possibly having a relationship to glaucoma.
How macular OCT scanning affects glaucoma evaluationLet’s examine what this specific (and separate) scan pattern can offer diagnostically
16 most popular stories of 2016
16 most popular stories of 2016Here is your roundup of what made top news in 2016!
6 things PCPs should know about glaucomaGlaucoma is a leading cause of blindness, a problem which is made even more serious by the fact that many patients do not notice any symptoms until it is too late to prevent permanent blindness.
Looking back at 2016
Looking back at 2016Before the new year gets too far along, let’s take a brief look at the happenings in the pages of Optometry Times during 2016.
Drug therapies, delivery systems advance for glaucoma carePharmacologic products and devices in development continue to gain momentum in the glaucoma treatment armamentarium.
MIGS devices lead glaucoma surgical innovation in 2016A single event stood out in everyone’s mind when Ophthalmology Times asked experts to think back on the year in glaucoma surgery: the July 29 approval by the U.S. Food and Drug Administration (FDA) of the CyPass Micro-Stent.
Glaucoma 360 approaches disease from every angleResearch. Industry. Philanthropy. These three facets—each with a unique purpose—will come together for the 2017 installment of the annual Glaucoma Research Foundation (GRF) Glaucoma 360 meeting. The three-day event will occur Feb. 2 to 4, 2016.